JP2007508319A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007508319A5 JP2007508319A5 JP2006534429A JP2006534429A JP2007508319A5 JP 2007508319 A5 JP2007508319 A5 JP 2007508319A5 JP 2006534429 A JP2006534429 A JP 2006534429A JP 2006534429 A JP2006534429 A JP 2006534429A JP 2007508319 A5 JP2007508319 A5 JP 2007508319A5
- Authority
- JP
- Japan
- Prior art keywords
- immunization
- administration
- noi
- composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 33
- 230000003053 immunization Effects 0.000 claims 23
- 238000002649 immunization Methods 0.000 claims 23
- 210000001744 T-lymphocyte Anatomy 0.000 claims 15
- 108090000623 proteins and genes Proteins 0.000 claims 11
- 102000004169 proteins and genes Human genes 0.000 claims 11
- 238000000034 method Methods 0.000 claims 8
- 108020004705 Codon Proteins 0.000 claims 6
- 239000002671 adjuvant Substances 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 102000009016 Cholera Toxin Human genes 0.000 claims 4
- 108010049048 Cholera Toxin Proteins 0.000 claims 4
- 241000725303 Human immunodeficiency virus Species 0.000 claims 4
- 238000003556 assay Methods 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 230000005867 T cell response Effects 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 230000001024 immunotherapeutic effect Effects 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 101710146739 Enterotoxin Proteins 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 claims 1
- 101710177291 Gag polyprotein Proteins 0.000 claims 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 1
- 101710125418 Major capsid protein Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 241000607626 Vibrio cholerae Species 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000147 enterotoxin Substances 0.000 claims 1
- 231100000655 enterotoxin Toxicity 0.000 claims 1
- 108700004026 gag Genes Proteins 0.000 claims 1
- 101150098622 gag gene Proteins 0.000 claims 1
- 102000018146 globin Human genes 0.000 claims 1
- 108060003196 globin Proteins 0.000 claims 1
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 210000003071 memory t lymphocyte Anatomy 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 238000005457 optimization Methods 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 238000011144 upstream manufacturing Methods 0.000 claims 1
- 229940118696 vibrio cholerae Drugs 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51008603P | 2003-10-10 | 2003-10-10 | |
| US52657103P | 2003-12-04 | 2003-12-04 | |
| US56777104P | 2004-05-05 | 2004-05-05 | |
| PCT/US2004/033391 WO2005035779A2 (en) | 2003-10-10 | 2004-10-12 | Method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007508319A JP2007508319A (ja) | 2007-04-05 |
| JP2007508319A5 true JP2007508319A5 (cg-RX-API-DMAC7.html) | 2008-02-21 |
Family
ID=34437668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006534429A Withdrawn JP2007508319A (ja) | 2003-10-10 | 2004-10-12 | 方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20070026015A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1675596A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2007508319A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20060123138A (cg-RX-API-DMAC7.html) |
| CN (1) | CN1889963A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004280630A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0415202A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2542295A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA012066B1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL174849A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA06003977A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20062081L (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ547042A (cg-RX-API-DMAC7.html) |
| SG (1) | SG146662A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005035779A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA010056B1 (ru) | 2003-10-10 | 2008-06-30 | Паудерджект Вэксинс, Инк. | Конструкции нуклеиновых кислот |
| US9090673B2 (en) * | 2003-12-12 | 2015-07-28 | City Of Hope | Synthetic conjugate of CpG DNA and T-help/CTL peptide |
| GB0507997D0 (en) * | 2005-02-01 | 2005-05-25 | Powderject Vaccines Inc | Nucleic acid constructs |
| NZ601439A (en) | 2005-06-08 | 2012-11-30 | Brigham & Womens Hospital | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway |
| CA2623531C (en) | 2005-10-07 | 2013-12-10 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Matrix metalloproteinase 11 vaccine |
| CA2658484A1 (en) | 2006-07-20 | 2008-01-24 | Vical Incorporated | Compositions and methods for vaccinating against hsv-2 |
| NZ596237A (en) * | 2006-12-27 | 2012-07-27 | Dana Farber Cancer Inst Inc | Compositions and methods for the treatment of infections and tumors |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| WO2009127666A2 (en) * | 2008-04-15 | 2009-10-22 | Glaxosmithkline Biologicals S.A. | Method and compositions |
| JP5520961B2 (ja) | 2008-11-28 | 2014-06-11 | エモリー ユニバーシティ | 感染症および腫瘍を処置するための方法 |
| BRPI1009892A2 (pt) * | 2009-03-24 | 2016-03-15 | Transgène S A | método ex-vivo para avaliar a eficácia de um tratamento em um paciente, e, kit para testar se um paciente está respondendo terapeuticamente a um método de tratamento compreendendo administração de uma composição imunogênica |
| WO2014150179A1 (en) * | 2013-03-15 | 2014-09-25 | Rush University Medical Center | Pseudomonas exotoxins for cancer treatment |
| GB201322626D0 (en) | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
| MA40783A (fr) | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population |
| GB201500374D0 (en) | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
| US11559570B2 (en) | 2015-05-15 | 2023-01-24 | CureVac SE | Prime-boost regimens involving administration of at least one mRNA construct |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5593972A (en) * | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| US6183746B1 (en) * | 1997-10-09 | 2001-02-06 | Zycos Inc. | Immunogenic peptides from the HPV E7 protein |
| CA2330526A1 (en) * | 1998-06-24 | 1999-12-29 | Innogenetics N.V. | Particles of hcv envelope proteins: use for vaccination |
| BR0012740A (pt) * | 1999-07-12 | 2002-05-28 | Genesis Res & Dev Corp Ltd | Compostos para tratamento de distúrbios do sistema infeccioso e imune e métodos para seu emprego |
| EP1311278A4 (en) * | 2000-08-07 | 2005-01-05 | Sloan Kettering Institutefor C | METHOD AND IMMUNIZATION COMPOSITION USING MIXED POOLS OF NUCLEIC ACIDS OR MUTED PEPTIDES |
| CA2422524A1 (en) * | 2000-09-25 | 2002-03-28 | Motoyuki Yamashita | Pei: dna vector formulations for in vitro and in vivo gene delivery |
| DE60325838D1 (de) * | 2002-03-19 | 2009-03-05 | Glaxo Group Ltd | Imidazoquinolinamine als adjuvantien für hiv dna vakzine |
| GB0206461D0 (en) * | 2002-03-19 | 2002-05-01 | Glaxo Group Ltd | Improvements in vaccination |
| DE60335350D1 (de) * | 2002-03-19 | 2011-01-27 | Powderject Res Ltd | Adjuvantien für dns impstoffe basierend auf imidazochinoline |
| US20030190308A1 (en) * | 2002-03-19 | 2003-10-09 | Braun Ralph P. | Adjuvant |
-
2004
- 2004-10-12 NZ NZ547042A patent/NZ547042A/en unknown
- 2004-10-12 MX MXPA06003977A patent/MXPA06003977A/es not_active Application Discontinuation
- 2004-10-12 SG SG200806935-3A patent/SG146662A1/en unknown
- 2004-10-12 EA EA200600738A patent/EA012066B1/ru not_active IP Right Cessation
- 2004-10-12 CN CNA2004800364591A patent/CN1889963A/zh active Pending
- 2004-10-12 WO PCT/US2004/033391 patent/WO2005035779A2/en not_active Ceased
- 2004-10-12 BR BRPI0415202-6A patent/BRPI0415202A/pt not_active IP Right Cessation
- 2004-10-12 JP JP2006534429A patent/JP2007508319A/ja not_active Withdrawn
- 2004-10-12 AU AU2004280630A patent/AU2004280630A1/en not_active Abandoned
- 2004-10-12 CA CA002542295A patent/CA2542295A1/en not_active Abandoned
- 2004-10-12 US US10/574,922 patent/US20070026015A1/en not_active Abandoned
- 2004-10-12 KR KR1020067009022A patent/KR20060123138A/ko not_active Ceased
- 2004-10-12 EP EP04794672A patent/EP1675596A4/en not_active Withdrawn
-
2006
- 2006-04-06 IL IL174849A patent/IL174849A0/en unknown
- 2006-05-09 NO NO20062081A patent/NO20062081L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12090200B2 (en) | Methods of producing cells resistant to HIV infection | |
| JP2007508319A5 (cg-RX-API-DMAC7.html) | ||
| Vogel et al. | Multispecific Vaccine-Induced Mucosal Cytotoxic TLymphocytes Reduce Acute-Phase Viral Replication but Fail inLong-Term Control of Simian Immunodeficiency VirusSIVmac239 | |
| AU2017292582B2 (en) | HIV pre-immunization and immunotherapy | |
| Nel et al. | Nano-enabled COVID-19 vaccines: meeting the challenges of durable antibody plus cellular immunity and immune escape | |
| Ko et al. | Optimization of codon usage enhances the immunogenicity of a DNA vaccine encoding mycobacterial antigen Ag85B | |
| JP2008526764A (ja) | 免疫応答の誘導におけるｃｄ４＋細胞の回避方法 | |
| AU2002362368B2 (en) | HIV-gag codon-optimised DNA vaccines | |
| Lu et al. | Macrophage inflammatory protein-1α (MIP-1α) expression plasmid enhances DNA vaccine-induced immune response against HIV-1 | |
| TWI845955B (zh) | Hiv疫苗以及製造及使用方法 | |
| CN101104636A (zh) | 来自gag p17和p24保守区域的HIV肽以及它们在例如疫苗中的应用 | |
| ES2288885T3 (es) | Minigenes optimizados y peptidos codificados por los mismos. | |
| Verma et al. | Impact of Th1 CD4 follicular helper T cell skewing on antibody responses to an HIV-1 vaccine in rhesus macaques | |
| BR112019014082A2 (pt) | Imunoterapia para hiv sem etapa de pré-imunização | |
| Wang et al. | Effective induction of simian immunodeficiency virus-specific systemic and mucosal immune responses in primates by vaccination with proviral DNA producing intact but noninfectious virions | |
| JP2006500035A (ja) | ヘルペスウイルス科の核酸配列および／またはポリペプチド配列を含むワクチンの同定方法およびワクチン接種用組成物 | |
| Viegas et al. | Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design | |
| Bazhan et al. | Designing and engineering of DNA-vaccine construction encoding multiple CTL-epitopes of major HIV-1 antigens | |
| Feng et al. | Induction of CD8+ T‐lymphocyte responses to a secreted antigen of Mycobacterium tuberculosis by an attenuated vaccinia virus | |
| JP2018521030A (ja) | Ｒｓｖおよびノロウイルス抗原の小腸送達のための製剤 | |
| Richert et al. | Cytokine and gene transcription profiles of immune responses elicited by HIV lipopeptide vaccine in HIV-negative volunteers | |
| JP2014508762A (ja) | ＳＩＶ／ＨＩＶからの防御を目的とする、組合せ細胞ベースのｇｐ９６−Ｉｇ−ＳＩＶ／ＨＩＶ、組換えｇｐ１２０タンパク質のワクチン接種 | |
| CN102978219B (zh) | 一种弧菌交叉保护性抗原及其制备方法和应用 | |
| EP3941518A1 (en) | Universal crimean congo haemorrhagic fever virus (cchfv) vaccine | |
| Bagley et al. | Immunogenicity of DNA vaccines that direct the coincident expression of the 120 kDa glycoprotein of human immunodeficiency virus and the catalytic domain of cholera toxin |